A decision aid for intensity-modulated radiation-therapy plan selection in prostate cancer based on a prognostic Bayesian network and a Markov model
暂无分享,去创建一个
Ira J. Kalet | Mark H. Phillips | Jason N. Doctor | Wade P. Smith | Jürgen Meyer | M. Phillips | J. Doctor | I. Kalet | Jürgen Meyer | W. Smith
[1] Alan W Partin,et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.
[2] Anthony V D'Amico,et al. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer , 2007, Cancer.
[3] William Speier,et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] L. Muren,et al. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. , 2008, International journal of radiation oncology, biology, physics.
[5] C. Burman,et al. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. , 1989, International journal of radiation oncology, biology, physics.
[6] J. Lyman. Complication probability as assessed from dose-volume histograms. , 1985, Radiation research. Supplement.
[7] E. Venkatraman,et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A B Wolbarst,et al. Optimization of radiation therapy, III: A method of assessing complication probabilities from dose-volume histograms. , 1987, International journal of radiation oncology, biology, physics.
[9] Di Yan,et al. Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models. , 2007, International journal of radiation oncology, biology, physics.
[10] Susan T. Stewart,et al. Utilities For Prostate Cancer Health States in Men Aged 60 and Older , 2005, Medical care.
[11] Susan T Stewart,et al. Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time. , 2004, Urology.
[12] Finn V. Jensen,et al. Bayesian Networks and Decision Graphs , 2001, Statistics for Engineering and Information Science.
[13] James D. Cox,et al. Consensus statement: Guidelines for PSA following radiation therapy , 1997 .
[14] F. Hamdy,et al. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis , 2008, BJU international.
[15] Joos V Lebesque,et al. Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling. , 2006, International journal of radiation oncology, biology, physics.
[16] Jian Z. Wang,et al. Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose. , 2002, Medical physics.
[17] Charles R. Thomas,et al. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. , 2006, International journal of radiation oncology, biology, physics.
[18] Leyuan Shi,et al. A multiplan treatment-planning framework: a paradigm shift for intensity-modulated radiotherapy. , 2007, International journal of radiation oncology, biology, physics.
[19] K. Burnham,et al. Optimization of beam orientation in radiotherapy using planar geometry. , 1998, Physics in medicine and biology.
[20] S. Pauker,et al. The Markov Process in Medical Prognosis , 1983, Medical decision making : an international journal of the Society for Medical Decision Making.
[21] Franca Foppiano,et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. , 2003, International journal of radiation oncology, biology, physics.
[22] T. Lawrence,et al. Ouabain sensitizes tumor cells but not normal cells to radiation. , 1987, International journal of radiation oncology, biology, physics.
[23] The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma , 2001, Cancer.
[24] José Mira Mira,et al. NasoNet, modeling the spread of nasopharyngeal cancer with networks of probabilistic events in discrete time , 2002, Artif. Intell. Medicine.
[25] J. Beck,et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. , 2006, International journal of radiation oncology, biology, physics.
[26] David J. Spiegelhalter,et al. Probabilistic Networks and Expert Systems , 1999, Information Science and Statistics.
[27] A. Niemierko. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. , 1997, Medical physics.
[28] Jürgen Meyer,et al. Application of influence diagrams to prostate intensity-modulated radiation therapy plan selection , 2004, Physics in medicine and biology.
[29] Evert de Jonge,et al. Prognostic Bayesian networks: I: Rationale, learning procedure, and clinical use , 2007, J. Biomed. Informatics.
[30] John B. Wong,et al. The Influence of Influence Diagrams in Medicine , 2005, Decis. Anal..
[31] P. Lucas,et al. Computer-based Decision Support in the Management of Primary Gastric non-Hodgkin Lymphoma , 1998, Methods of Information in Medicine.
[32] J R Beck,et al. Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.
[33] D. Grignon,et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. Weinstein,et al. Decision Making in Health and Medicine , 2001 .
[35] Lei Dong,et al. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. , 2007, International journal of radiation oncology, biology, physics.
[36] D. Hussey. American Society for Therapeutic Radiology and Oncology , 2001 .
[37] P. Walsh,et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. , 1993, The Journal of urology.
[38] F Foppiano,et al. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[39] L. Marks,et al. A dose‐volume‐based tool for evaluating and ranking IMRT treatment plans , 2004, Journal of applied clinical medical physics.
[40] M G Kahn,et al. Objective evaluation of 3-D radiation treatment plans: a decision-analytic tool incorporating treatment preferences of radiation oncologists. , 1993, International journal of radiation oncology, biology, physics.
[41] A. Hanlon,et al. Defining the optimal radiation dose with three‐dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques , 2001, Cancer.
[42] Peter J. F. Lucas,et al. Bayesian networks in biomedicine and health-care , 2004, Artif. Intell. Medicine.